Close menu




November 10th, 2020 | 09:35 CET

BioNTech, RYU Apparel, TUI: Breakthroughs and unicorns!

  • Investments
Photo credits: pixabay.com

The world is taking a deep breath, at least for now. As many had hoped, the voting out of US President Donald Trump was sealed this past weekend. Vaccination research is also progressing as a result of the corona pandemic. Despite rising case numbers, fewer resources in intensive care units, and the threat of an increased lockdown possibly beyond Christmas, there is a silver lining. People long for normality and the finer things in life.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA74979J4072 , US09075V1026 , DE000TUAG000

Table of contents:


    Unicorn in the fashion market

    The fashion label, RYU Apparel, is a name to remember. The Canadians have ambitious plans. According to management, the goal is to build a billion-dollar Company by 2030. "Respect Your Universe", as the Company name means when spelt out, wants to create a perfect symbiosis of the three areas of life - fashion, sport and lifestyle - in its collections. This promises to result in significant leverage in sales compared to the industry average.

    Sustainability in the foreground

    RYU Apparel, based in Vancouver, Canada, focuses on sustainability and follows the blue path taken by Bluesign. "The Blue Way" stands for the vision and mission of responsible and sustainable textile manufacturing. Based on a holistic approach, the project follows the path of every single textile product along its production process. It makes improvements at every stage - from production to the final product.

    Strong conditions created

    Almost everything has changed at RYU Apparel this year. The troubled Company replaced nearly the entire management team. The new CEO, Cesare Fazari, has been in position since March. Fazari has an extremely successful history as a serial founder in the fields of real estate, biotechnology and fintech and has acted as a venture capital investor in several companies that achieved billion-dollar valuations. In addition to the new CEO, several players with capital markets experience also came on board.

    Capital increase as the starting signal

    After a capital cut of 10:1 in the summer, the new management at RYU took the next step at the end of October. Thus one could recruit in a private placement equity capital of CAD 4.8 million at CAD 0.05 each. With scarcely one fifth, the management itself is involved. In addition to marketing measures, the Canadians want to continue to invest liquidity in improving their online store, particularly in-house. In addition, the production "Made in Canada" will be resumed.

    Strategy consultant brings the push

    The commitment of Joel Primus, the co-founder of Naked Brands Inc., as a strategy consultant, is considered a sensation in the industry. Primus was the creative visionary behind numerous products in naked underwear, established retail sales at Holt Renfrew, Nordstrom, Hudson's Bay and Bloomingdales, brokered partnerships with celebrities and coordinated the listing of Naked Brands Inc. on Nasdaq. The Company currently has a market capitalization of EUR 12 million. The course for growth is set here, but whether it will reach the unicorn is questionable. However, management has demonstrated this.

    On the last meters

    BioNTech and Pfizer seem to rock it. The first data announced from the start of a pivotal Phase 3 clinical trial for its vaccine candidate BNT162b2. The potential vaccine achieved an efficacy rate of more than 90 percent seven days after the second dose, the Companies announced. Meaning that protection is achieved 28 days after the start of the vaccination, the Companies added. BioNTech CEO and co-founder Ugur Sahin called it a "significant step" in the fight against the coronavirus, while his partner, Pfizer CEO Albert Bourla, called it a momentous day for science and humanity. As expected, BioNTech's shares went through the roof and, at an all-time high of almost USD 115 and closed at USD 104.80, an increase of 14%.

    Nightmare over?

    The announcement of a possible soon-to-be-approved vaccine has benefited the badly hit tourism and aviation stocks. Both TUI and Lufthansa are rising in intervals by more than 25%, but just how sustainable these gains are will become apparent in the next few days. The next step on the charts is the battle for the crucial 200-day line.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read